{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T08:11:11Z","timestamp":1787731871368,"version":"build-2784847793"},"reference-count":76,"publisher":"Radcliffe Medical Media Ltd","license":[{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/legalcode"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur Cardiol"],"abstract":"<jats:p>Frailty has received increasing scientific attention as a potential explanation for adverse health outcomes among older adults. In cardio-oncology, frailty is particularly relevant due to the dual burden of cardiovascular disease and cancer, both of which accelerate the general decline in health associated with ageing. Therefore, understanding and addressing frailty in cardio-oncology has paramount importance for optimising patient outcomes, personalising treatment plans, and improving quality of life. In this review, we aim to discuss: the pathophysiology of frailty in the context of cardio-oncology; the common frailty definitions used in observational studies and in clinical drug trials among patients with cancer; the challenges of frailty assessments in cardio-oncology; and the need to incorporate frailty into cardiovascular risk assessment tools in older patients with cancer. Further research is needed to better understand the underlying mechanisms linking frailty to cardiotoxicity and to explore potential interventions that may mitigate these risks in cancer patients.<\/jats:p>","DOI":"10.15420\/ecr.2025.57","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T10:17:48Z","timestamp":1764325068000},"source":"Crossref","is-referenced-by-count":2,"title":["The Role of Frailty in Cardio-oncology and its Challenges"],"prefix":"10.15420","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-5072-9998","authenticated-orcid":false,"given":"Erkihun","family":"Amsalu","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0384j8v12","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Sydney"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0234-6596","authenticated-orcid":false,"given":"Tan Van","family":"Nguyen","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02hwy9s76","id-type":"ROR","asserted-by":"publisher"}],"name":"Thong Nhat Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3635-421X","authenticated-orcid":false,"given":"Harry","family":"Klimis","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/025kb2624","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Medicine and Pharmacy at Ho Chi Minh City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9800-5296","authenticated-orcid":false,"given":"Mark","family":"Woodward","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04h0zjx60","id-type":"ROR","asserted-by":"publisher"}],"name":"The George Institute for Global Health"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8836-8920","authenticated-orcid":false,"given":"Tu","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6096","published-online":{"date-parts":[[2025,11,26]]},"reference":[{"key":"ref0","doi-asserted-by":"crossref","unstructured":"Reddy P, Shenoy C, Blaes AH. Cardio-oncology in the older adult. J Geriatr Oncol 2017;8:308\u201314. https:\/\/doi.org\/10.1016\/j.jgo.2017.04.001; PMID: 28499724. DOI: 10.1016\/j.jgo.2017.04.001","DOI":"10.1016\/j.jgo.2017.04.001"},{"key":"ref1","unstructured":"Lyon AR, L\u00f3pez-Fern\u00e1ndez T, Couch LS, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J 2022;43:4229\u2013361. https:\/\/doi.org\/10.1093\/eurheartj\/ehac244; PMID: 36017568."},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Hayek SS, Ganatra S, Lenneman C, et al. Preparing the cardiovascular workforce to care for oncology patients: JACC review topic of the week. J Am Coll Cardiol 2019;73:2226\u201335. https:\/\/doi.org\/10.1016\/j.jacc.2019.02.041; PMID: 31047011. DOI: 10.1016\/j.jacc.2019.02.041","DOI":"10.1016\/j.jacc.2019.02.041"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Herrmann J. Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia. Nat Rev Cardiol 2020;17:474\u2013502. https:\/\/doi.org\/10.1038\/s41569-020-0348-1; PMID: 32231332. DOI: 10.1038\/s41569-020-0348-1","DOI":"10.1038\/s41569-020-0348-1"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Clegg A, Young J, Iliffe S, et al. Frailty in elderly people. Lancet 2013;381:752\u201362. https:\/\/doi.org\/10.1016\/S0140-6736(12)62167-9; PMID: 23395245. DOI: 10.1016\/S0140-6736(12)62167-9","DOI":"10.1016\/S0140-6736(12)62167-9"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Amsalu E, Zhang Y, Harrison C, et al. Exploring frailty in the intersection of cardiovascular disease and cancer in older people. Int J Environ Res Public Health 2023;20:7105. https:\/\/doi.org\/10.3390\/ijerph20237105; PMID: 38063535. DOI: 10.3390\/ijerph20237105","DOI":"10.3390\/ijerph20237105"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Kojima G, Liljas AEM, Iliffe S. Frailty syndrome: implications and challenges for health care policy. Risk Manag Healthc Policy 2019;12:23\u201330. https:\/\/doi.org\/10.2147\/RMHP.S168750; PMID: 30858741. DOI: 10.2147\/RMHP.S168750","DOI":"10.2147\/RMHP.S168750"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Richter D, Guasti L, Walker D, et al. Frailty in cardiology: definition, assessment and clinical implications for general cardiology. A consensus document of the Council for Cardiology Practice (CCP), Association for Acute Cardio Vascular Care (ACVC), Association of Cardiovascular Nursing and Allied Professions (ACNAP), European Association of Preventive Cardiology (EAPC), European Heart Rhythm Association (EHRA), Council on Valvular Heart Diseases (VHD), Council on Hypertension (CHT), Council of Cardio-Oncology (CCO), Working Group (WG) Aorta and Peripheral Vascular Diseases, WG e-Cardiology, WG Thrombosis, of the European Society of Cardiology, European Primary Care Cardiology Society (EPCCS). Eur J Prev Cardiol 2022;29:216\u201327. https:\/\/doi.org\/10.1093\/eurjpc\/zwaa167; PMID: 34270717. DOI: 10.1093\/eurjpc\/zwaa167","DOI":"10.1093\/eurjpc\/zwaa167"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"O\u2019Caoimh R, Sezgin D, O\u2019Donovan MR, et al. Prevalence of frailty in 62 countries across the world: a systematic review and meta-analysis of population-level studies. Age Ageing 2021;50:96\u2013104. https:\/\/doi.org\/10.1093\/ageing\/afaa219; PMID: 33068107. DOI: 10.1093\/ageing\/afaa219","DOI":"10.1093\/ageing\/afaa219"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Handforth C, Clegg A, Young C, et al. The prevalence and outcomes of frailty in older cancer patients: a systematic review. Ann Oncol 2015;26:1091\u2013101. https:\/\/doi.org\/10.1093\/annonc\/mdu540; PMID: 25403592. DOI: 10.1093\/annonc\/mdu540","DOI":"10.1093\/annonc\/mdu540"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Pearce J, Martin S, Heritage S, et al. Frailty and outcomes in adults undergoing systemic anticancer treatment: a systematic review and meta-analysis. J Natl Cancer Inst 2025;117:1316\u201339. https:\/\/doi.org\/10.1093\/jnci\/djaf017; PMID: 39886936. DOI: 10.1093\/jnci\/djaf017","DOI":"10.1093\/jnci\/djaf017"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Hanlon E, Diaz ANR, Sedrak MS, et al. Cancer therapy-associated cardiotoxicity: a look at frailty. J Geriatr Oncol 2024;15:101835. https:\/\/doi.org\/10.1016\/j.jgo.2024.101835; PMID: 39048388. DOI: 10.1016\/j.jgo.2024.101835","DOI":"10.1016\/j.jgo.2024.101835"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"George M, Smith A, Sabesan S, Ranmuthugala G. Physical comorbidities and their relationship with cancer treatment and its outcomes in older adult populations: systematic review. JMIR Cancer 2021;7:e26425. https:\/\/doi.org\/10.2196\/26425; PMID: 34643534. DOI: 10.2196\/26425","DOI":"10.2196\/26425"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Ioffe D, Bhatia-Patel SC, Gandhi S, et al. Cardiovascular concerns, cancer treatment, and biological and chronological aging in cancer: JACC family series. JACC CardioOncol 2024;6:143\u201358. https:\/\/doi.org\/10.1016\/j.jaccao.2024.02.001; PMID: 38774000. DOI: 10.1016\/j.jaccao.2024.02.001","DOI":"10.1016\/j.jaccao.2024.02.001"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Sato R, Vatic M, Peixoto da Fonseca GW, et al. Biological basis and treatment of frailty and sarcopenia. Cardiovasc Res 2024;120:982\u201398. https:\/\/doi.org\/10.1093\/cvr\/cvae073; PMID: 38828887. DOI: 10.1093\/cvr\/cvae073","DOI":"10.1093\/cvr\/cvae073"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Goede V. Frailty and cancer: current perspectives on assessment and monitoring. Clin Interv Aging 2023;18:505\u201321. https:\/\/doi.org\/10.2147\/CIA.S365494; PMID: 37013130. DOI: 10.2147\/CIA.S365494","DOI":"10.2147\/CIA.S365494"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Clegg A, Young J. The frailty syndrome. Clin Med (Lond) 2011;11:72\u20135. https:\/\/doi.org\/10.7861\/clinmedicine.11-1-72; PMID: 21404792. DOI: 10.7861\/clinmedicine.11-1-72","DOI":"10.7861\/clinmedicine.11-1-72"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Soysal P, Stubbs B, Lucato P, et al. Inflammation and frailty in the elderly: a systematic review and meta-analysis. Ageing Res Rev 2016;31:1\u20138. https:\/\/doi.org\/10.1016\/j.arr.2016.08.006; PMID: 27592340. DOI: 10.1016\/j.arr.2016.08.006","DOI":"10.1016\/j.arr.2016.08.006"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Xie Y, Liu F, Wu Y, et al. Inflammation in cancer: therapeutic opportunities from new insights. Mol Cancer 2025;24:51. https:\/\/doi.org\/10.1186\/s12943-025-02243-8; PMID: 39994787. DOI: 10.1186\/s12943-025-02243-8","DOI":"10.1186\/s12943-025-02243-8"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420:860\u20137. https:\/\/doi.org\/10.1038\/nature01322; PMID: 12490959. DOI: 10.1038\/nature01322","DOI":"10.1038\/nature01322"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Anjanappa M, Corden M, Green A, et al. Sarcopenia in cancer: risking more than muscle loss. Tech Innov Patient Support Radiat Oncol 2020;16:50\u20137. https:\/\/doi.org\/10.1016\/j.tipsro.2020.10.001; PMID: 33385074. DOI: 10.1016\/j.tipsro.2020.10.001","DOI":"10.1016\/j.tipsro.2020.10.001"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Lavalle S, Valerio MR, Masiello E, et al. Unveiling the intricate dance: how cancer orchestrates muscle wasting and sarcopenia. In Vivo 2024;38:1520\u20139. https:\/\/doi.org\/10.21873\/invivo.13602; PMID: 38936901. DOI: 10.21873\/invivo.13602","DOI":"10.21873\/invivo.13602"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"M\u00e0rmol JM, Carlsson M, Raun SH, et al. Insulin resistance in patients with cancer: a systematic review and meta-analysis. Acta Oncol 2023;62:364\u201371. https:\/\/doi.org\/10.1080\/0284186X.2023.2197124; PMID: 37042166. DOI: 10.1080\/0284186X.2023.2197124","DOI":"10.1080\/0284186X.2023.2197124"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Sahu K, Langeh U, Singh C, Singh A. Crosstalk between anticancer drugs and mitochondrial functions. Curr Res Pharmacol Drug Discov 2021;2:100047. https:\/\/doi.org\/10.1016\/j.crphar.2021.100047; PMID: 34909674. DOI: 10.1016\/j.crphar.2021.100047","DOI":"10.1016\/j.crphar.2021.100047"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Dominic A, Hamilton D, Abe JI. Mitochondria and chronic effects of cancer therapeutics: the clinical implications. J Thromb Thrombolysis 2021;51:884\u20139. https:\/\/doi.org\/10.1007\/s11239-020-02313-2; PMID: 33079380. DOI: 10.1007\/s11239-020-02313-2","DOI":"10.1007\/s11239-020-02313-2"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Musicco C, Signorile A, Pesce V, et al. Mitochondria deregulations in cancer offer several potential targets of therapeutic interventions. Int J Mol Sci 2023;24:10420. https:\/\/doi.org\/10.3390\/ijms241310420; PMID: 37445598. DOI: 10.3390\/ijms241310420","DOI":"10.3390\/ijms241310420"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Ezeoke CC, Morley JE. Pathophysiology of anorexia in the cancer cachexia syndrome. J Cachexia Sarcopenia Muscle 2015;6:287\u2013302. https:\/\/doi.org\/10.1002\/jcsm.12059; PMID: 26675762. DOI: 10.1002\/jcsm.12059","DOI":"10.1002\/jcsm.12059"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Yeom E, Yu K. Understanding the molecular basis of anorexia and tissue wasting in cancer cachexia. Exp Mol Med 2022;54:426\u201332. https:\/\/doi.org\/10.1038\/s12276-022-00752-w; PMID: 35388147. DOI: 10.1038\/s12276-022-00752-w","DOI":"10.1038\/s12276-022-00752-w"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Bonnefoy M, Berrut G, Lesourd B, et al. Frailty and nutrition: searching for evidence. J Nutr Health Aging 2015;19:250\u20137. https:\/\/doi.org\/10.1007\/s12603-014-0568-3; PMID: 25732208. DOI: 10.1007\/s12603-014-0568-3","DOI":"10.1007\/s12603-014-0568-3"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Ng TP, Feng L, Nyunt MSZ, et al. Nutritional, physical, cognitive, and combination interventions and frailty reversal among older adults: a randomized controlled trial. Am J Med 2015;128:1225\u201336.e1. https:\/\/doi.org\/10.1016\/j.amjmed.2015.06.017; PMID: 26159634. DOI: 10.1016\/j.amjmed.2015.06.017","DOI":"10.1016\/j.amjmed.2015.06.017"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Kim C-O, Lee K-R. Preventive effect of protein-energy supplementation on the functional decline of frail older adults with low socioeconomic status: a community-based randomized controlled study. J Gerontol A Biol Sci Med Sci 2013;68:309\u201316. https:\/\/doi.org\/10.1093\/gerona\/gls167; PMID: 22879453. DOI: 10.1093\/gerona\/gls167","DOI":"10.1093\/gerona\/gls167"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Ni J, Zhang L. Cancer cachexia: definition, staging, and emerging treatments. Cancer Manag Res 2020;12:5597\u2013605. https:\/\/doi.org\/10.2147\/CMAR.S261585; PMID: 32753972. DOI: 10.2147\/CMAR.S261585","DOI":"10.2147\/CMAR.S261585"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Petermann-Rocha F, Pell JP, Celis-Morales C, Ho FK. Frailty, sarcopenia, cachexia and malnutrition as comorbid conditions and their associations with mortality: a prospective study from UK Biobank. J Public Health (Oxf) 2022;44:e172\u201380. https:\/\/doi.org\/10.1093\/pubmed\/fdaa226; PMID: 33423060. DOI: 10.1093\/pubmed\/fdaa226","DOI":"10.1093\/pubmed\/fdaa226"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Volkova M, Russell R, 3rd. Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment. Curr Cardiol Rev 2011;7:214\u201320. https:\/\/doi.org\/10.2174\/157340311799960645; PMID: 22758622. DOI: 10.2174\/157340311799960645","DOI":"10.2174\/157340311799960645"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Sayegh N, Yirerong J, Agarwal N, et al. Cardiovascular toxicities associated with tyrosine kinase inhibitors. Curr Cardiol Rep 2023;25:269\u201380. https:\/\/doi.org\/10.1007\/s11886-023-01845-2; PMID: 36795308. DOI: 10.1007\/s11886-023-01845-2","DOI":"10.1007\/s11886-023-01845-2"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Elmorsy EA, Saber S, Hamad RS, et al. Advances in understanding cisplatin-induced toxicity: molecular mechanisms and protective strategies. Eur J Pharm Sci 2024;203:106939. https:\/\/doi.org\/10.1016\/j.ejps.2024.106939; PMID: 39423903. DOI: 10.1016\/j.ejps.2024.106939","DOI":"10.1016\/j.ejps.2024.106939"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Wijerathne H, Langston JC, Yang Q, et al. Mechanisms of radiation-induced endothelium damage: emerging models and technologies. Radiother Oncol 2021;158:21\u201332. https:\/\/doi.org\/10.1016\/j.radonc.2021.02.007; PMID: 33581220. DOI: 10.1016\/j.radonc.2021.02.007","DOI":"10.1016\/j.radonc.2021.02.007"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Talha KM, Pandey A, Fudim M, et al. Frailty and heart failure: state-of-the-art review. J Cachexia Sarcopenia Muscle 2023;14:1959\u201372. https:\/\/doi.org\/10.1002\/jcsm.13306; PMID: 37586848. DOI: 10.1002\/jcsm.13306","DOI":"10.1002\/jcsm.13306"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Kojima G, Aoyama R, Tanabe M. Associations between social isolation and physical frailty in older adults: a systematic review and meta-analysis. J Am Med Dir Assoc 2022;23:e3\u20136. https:\/\/doi.org\/10.1016\/j.jamda.2022.06.012; PMID: 35810790. DOI: 10.1016\/j.jamda.2022.06.012","DOI":"10.1016\/j.jamda.2022.06.012"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Vaughan L, Corbin AL, Goveas JS. Depression and frailty in later life: a systematic review. Clin Interv Aging 2015;10:1947\u201358. https:\/\/doi.org\/10.2147\/CIA.S69632; PMID: 26719681. DOI: 10.2147\/CIA.S69632","DOI":"10.2147\/CIA.S69632"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Bergerot C, Jacobsen PB, Rosa WE, et al. Global unmet psychosocial needs in cancer care: health policy. EClinicalmedicine 2024;78:102942. https:\/\/doi.org\/10.1016\/j.eclinm.2024.102942; PMID: 39634034. DOI: 10.1016\/j.eclinm.2024.102942","DOI":"10.1016\/j.eclinm.2024.102942"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"Deng Y, Sato N. Global frailty screening tools: review and application of frailty screening tools from 2001 to 2023. Intractable Rare Dis Res 2024;13:1\u201311. https:\/\/doi.org\/10.5582\/irdr.2023.01113; PMID: 38404737. DOI: 10.5582\/irdr.2023.01113","DOI":"10.5582\/irdr.2023.01113"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"Azzopardi RV, Vermeiren S, Gorus E, et al. Linking frailty instruments to the international classification of functioning, disability, and health: a systematic review. J Am Med Dir Assoc 2016;17:1066.e1\u20131066.e11. https:\/\/doi.org\/10.1016\/j.jamda.2016.07.023; PMID: 27614932. DOI: 10.1016\/j.jamda.2016.07.023","DOI":"10.1016\/j.jamda.2016.07.023"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"Dent E, Lien C, Lim WS, et al. The Asia-Pacific clinical practice guidelines for the management of frailty. J Am Med Dir Assoc 2017;18:564\u201375. https:\/\/doi.org\/10.1016\/j.jamda.2017.04.018; PMID: 28648901. DOI: 10.1016\/j.jamda.2017.04.018","DOI":"10.1016\/j.jamda.2017.04.018"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"Ma L. Current situation of frailty screening tools for older adults. J Nutr Health Aging 2019;23:111\u20138. https:\/\/doi.org\/10.1007\/s12603-018-1123-4; PMID: 30569079. DOI: 10.1007\/s12603-018-1123-4","DOI":"10.1007\/s12603-018-1123-4"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 2001;56:M146\u201356. https:\/\/doi.org\/10.1093\/gerona\/56.3.m146; PMID: 11253156. DOI: 10.1093\/gerona\/56.3.M146","DOI":"10.1093\/gerona\/56.3.M146"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"Searle SD, Mitnitski A, Gahbauer EA, et al. A standard procedure for creating a frailty index. BMC Geriatr 2008;8:24. https:\/\/doi.org\/10.1186\/1471-2318-8-24; PMID: 18826625. DOI: 10.1186\/1471-2318-8-24","DOI":"10.1186\/1471-2318-8-24"},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"Rockwood K, Mitnitski A. Frailty defined by deficit accumulation and geriatric medicine defined by frailty. Clin Geriatr Med 2011;27:17\u201326. https:\/\/doi.org\/10.1016\/j.cger.2010.08.008; PMID: 21093719. DOI: 10.1016\/j.cger.2010.08.008","DOI":"10.1016\/j.cger.2010.08.008"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"Theou O, Haviva C, Wallace L, et al. How to construct a frailty index from an existing dataset in 10 steps. Age Ageing 2023;52:afad221. https:\/\/doi.org\/10.1093\/ageing\/afad221; PMID: 38124255. DOI: 10.1093\/ageing\/afad221","DOI":"10.1093\/ageing\/afad221"},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"Clegg A, Bates C, Young J, et al. Development and validation of an electronic frailty index using routine primary care electronic health record data. Age Ageing 2016;45:353\u201360. https:\/\/doi.org\/10.1093\/ageing\/afw039; PMID: 26944937. DOI: 10.1093\/ageing\/afw039","DOI":"10.1093\/ageing\/afw039"},{"key":"ref50","doi-asserted-by":"crossref","unstructured":"Wildiers H, Heeren P, Puts M, et al. International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer. J Clin Oncol 2014;32:2595\u2013603. https:\/\/doi.org\/10.1200\/JCO.2013.54.8347; PMID: 25071125. DOI: 10.1200\/JCO.2013.54.8347","DOI":"10.1200\/JCO.2013.54.8347"},{"key":"ref51","unstructured":"Mohile SG, Dale W, Somerfield MR, et al. Practical assessment and management of vulnerabilities in older patients receiving chemotherapy: ASCO guideline for geriatric oncology. J Clin Oncol 2018;36:2326\u201347. https:\/\/doi.org\/10.1200\/JCO.2018.78.8687; PMID: 29782209."},{"key":"ref52","doi-asserted-by":"crossref","unstructured":"Nguyen TN, Ahmad F, Lindley RI. Frailty in clinical drug trials: frailty assessments, subgroup analyses and outcomes. Br J Clin Pharmacol 2025;91:8\u201322. https:\/\/doi.org\/10.1111\/bcp.16034; PMID: 38509766. DOI: 10.1111\/bcp.16034","DOI":"10.1111\/bcp.16034"},{"key":"ref53","doi-asserted-by":"crossref","unstructured":"Auner HW, Gavriatopoulou M, Delimpasi S, et al. Effect of age and frailty on the efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma. Am J Hematol 2021;96:708\u201318. https:\/\/doi.org\/10.1002\/ajh.26172; PMID: 33755235. DOI: 10.1002\/ajh.26172","DOI":"10.1002\/ajh.26172"},{"key":"ref54","doi-asserted-by":"crossref","unstructured":"Mateos MV, Dimopoulos MA, Cavo M, et al. Daratumumab plus bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of ALCYONE. Clin Lymphoma Myeloma Leuk 2021;21:785\u201398. https:\/\/doi.org\/10.1016\/j.clml.2021.06.005; PMID: 34344638. DOI: 10.1016\/j.clml.2021.06.005","DOI":"10.1016\/j.clml.2021.06.005"},{"key":"ref55","doi-asserted-by":"crossref","unstructured":"Facon T, Cook G, Usmani SZ, et al. Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of Maia. Leukemia 2022;36:1066\u201377. https:\/\/doi.org\/10.1038\/s41375-021-01488-8; PMID: 34974527. DOI: 10.1038\/s41375-021-01488-8","DOI":"10.1038\/s41375-021-01488-8"},{"key":"ref56","doi-asserted-by":"crossref","unstructured":"Bringhen S, D\u2019Agostino M, Paris L, et al. Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: updated results of the EMN01 randomized trial. Haematologica 2020;105:1937\u201347. https:\/\/doi.org\/10.3324\/haematol.2019.226407; PMID: 31582542. DOI: 10.3324\/haematol.2019.226407","DOI":"10.3324\/haematol.2019.226407"},{"key":"ref57","doi-asserted-by":"crossref","unstructured":"Mo\u00efsi L, Mino JC, Guidet B, Vallet H. Frailty assessment in critically ill older adults: a narrative review. Ann Intensive Care 2024;14:93. https:\/\/doi.org\/10.1186\/s13613-024-01315-0; PMID: 38888743. DOI: 10.1186\/s13613-024-01315-0","DOI":"10.1186\/s13613-024-01315-0"},{"key":"ref58","doi-asserted-by":"crossref","unstructured":"Banna GL, Cantale O, Haydock MM, et al. International survey on frailty assessment in patients with cancer. Oncologist 2022;27:e796\u2013803. https:\/\/doi.org\/10.1093\/oncolo\/oyac133; PMID: 35905085. DOI: 10.1093\/oncolo\/oyac133","DOI":"10.1093\/oncolo\/oyac133"},{"key":"ref59","doi-asserted-by":"crossref","unstructured":"Patrizio E, Calvani R, Marzetti E, Cesari M. Physical functional assessment in older adults. J Frailty Aging 2021;10:141\u20139. https:\/\/doi.org\/10.14283\/jfa.2020.61; PMID: 33575703. DOI: 10.14283\/jfa.2020.61","DOI":"10.14283\/jfa.2020.61"},{"key":"ref60","doi-asserted-by":"crossref","unstructured":"Warnock C, Ulman J, Skilbeck J, Tod A. Patient and staff perspectives on the concept of frailty and its role in assessment and decision making in treatment for older people with lung cancer. Eur J Oncol Nurs 2024;71:102611. https:\/\/doi.org\/10.1016\/j.ejon.2024.102611; PMID: 38897102. DOI: 10.1016\/j.ejon.2024.102611","DOI":"10.1016\/j.ejon.2024.102611"},{"key":"ref61","doi-asserted-by":"crossref","unstructured":"Khan SS, Coresh J, Pencina MJ, et al. Novel prediction equations for absolute risk assessment of total cardiovascular disease incorporating cardiovascular-kidney-metabolic health: a scientific statement from the American Heart Association. Circulation 2023;148:1982\u20132004. https:\/\/doi.org\/10.1161\/CIR.0000000000001191; PMID: 37947094. DOI: 10.1161\/CIR.0000000000001191","DOI":"10.1161\/CIR.0000000000001191"},{"key":"ref62","unstructured":"SCORE2 working group and ESC Cardiovascular risk collaboration. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. Eur Heart J 2021;42:2439\u201354. https:\/\/doi.org\/10.1093\/eurheartj\/ehab309; PMID: 34120177."},{"key":"ref63","unstructured":"Lyon AR, Dent S, Stanway S, et al. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. Eur J Heart Fail 2020;22:1945\u201360. https:\/\/doi.org\/10.1002\/ejhf.1920; PMID: 32463967."},{"key":"ref64","doi-asserted-by":"crossref","unstructured":"Alsuhebany N, Alkhalaf H, Alshehri F, et al. Validation of the HFA-ICOS cardiovascular toxicity risk tool in chronic myeloid leukemia patients receiving tyrosine kinase inhibitors: real-world data from the Saudi population. J Clin Oncol 2025;43(16_suppl):e24009. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.e24009. DOI: 10.1200\/JCO.2025.43.16_suppl.e24009","DOI":"10.1200\/JCO.2025.43.16_suppl.e24009"},{"key":"ref65","doi-asserted-by":"crossref","unstructured":"Rivero-Santana B, Salda\u00f1a-Garc\u00eda J, Caro-Cod\u00f3n J, et al. Anthracycline-induced cardiovascular toxicity: validation of the Heart Failure Association and International Cardio-Oncology Society risk score. Eur Heart J 2025;46:273\u201384. https:\/\/doi.org\/10.1093\/eurheartj\/ehae496; PMID: 39106857. DOI: 10.1093\/eurheartj\/ehae818","DOI":"10.1093\/eurheartj\/ehae818"},{"key":"ref66","doi-asserted-by":"crossref","unstructured":"Fernando F, Andres MS, Claudiani S, et al. Cardiovascular events in CML patients treated with nilotinib: validation of the HFA-ICOS baseline risk score. Cardiooncology 2024;10:42. https:\/\/doi.org\/10.1186\/s40959-024-00245-x; PMID: 39010172. DOI: 10.1186\/s40959-024-00245-x","DOI":"10.1186\/s40959-024-00245-x"},{"key":"ref67","doi-asserted-by":"crossref","unstructured":"Soh CH, Marwick TH. Comparison of heart failure risk assessment tools among cancer survivors. Cardiooncology 2024;10:67. https:\/\/doi.org\/10.1186\/s40959-024-00267-5; PMID: 39394611. DOI: 10.1186\/s40959-024-00267-5","DOI":"10.1186\/s40959-024-00267-5"},{"key":"ref68","doi-asserted-by":"crossref","unstructured":"Cronin M, Crowley A, Davey MG, et al. Heart Failure Association-International Cardio-Oncology Society risk score validation in HER2-positive breast cancer. J Clin Med 2023;12:1278. https:\/\/doi.org\/10.3390\/jcm12041278; PMID: 36835818. DOI: 10.3390\/jcm12041278","DOI":"10.3390\/jcm12041278"},{"key":"ref69","doi-asserted-by":"crossref","unstructured":"Madaudo C, Di Lisi D, Cannat\u00e0 A, et al. Cardiovascular toxicity induced by TKIs in patients with chronic myeloid leukaemia: are women and men different? ESC Heart Fail 2025;12:1447\u201354. https:\/\/doi.org\/10.1002\/ehf2.15165; PMID: 39780756. DOI: 10.1002\/ehf2.15165","DOI":"10.1002\/ehf2.15165"},{"key":"ref70","doi-asserted-by":"crossref","unstructured":"Suntheralingam S, Fan CS, Calvillo-Arg\u00fcelles O, et al. Evaluation of risk prediction models to identify cancer therapeutics related cardiac dysfunction in women with HER2+ breast cancer. J Clin Med 2022;11:847. https:\/\/doi.org\/10.3390\/jcm11030847; PMID: 35160296. DOI: 10.3390\/jcm11030847","DOI":"10.3390\/jcm11030847"},{"key":"ref71","doi-asserted-by":"crossref","unstructured":"Battisti NML, Andres MS, Lee KA, et al. Incidence of cardiotoxicity and validation of the Heart Failure Association-International Cardio-Oncology Society risk stratification tool in patients treated with trastuzumab for HER2-positive early breast cancer. Breast Cancer Res Treat 2021;188:149\u201363. https:\/\/doi.org\/10.1007\/s10549-021-06192-w; PMID: 33818652. DOI: 10.1007\/s10549-021-06192-w","DOI":"10.1007\/s10549-021-06192-w"},{"key":"ref72","doi-asserted-by":"crossref","unstructured":"James K, Jamil Y, Kumar M, et al. Frailty and cardiovascular health. J Am Heart Assoc 2024;13:e031736. https:\/\/doi.org\/10.1161\/JAHA.123.031736; PMID: 39056350. DOI: 10.1161\/JAHA.123.031736","DOI":"10.1161\/JAHA.123.031736"},{"key":"ref73","doi-asserted-by":"crossref","unstructured":"Richardson S, Karunananthan S, Bergman H. I may be frail but I ain\u2019t no failure. Can Geriatr J 2011;14:24\u20138. https:\/\/doi.org\/10.5770\/cgj.v14i1.4; PMID: 23251307. DOI: 10.5770\/cgj.v14i1.4","DOI":"10.5770\/cgj.v14i1.4"},{"key":"ref74","doi-asserted-by":"crossref","unstructured":"Nicholson C, Meyer J, Flatley M, et al. Living on the margin: understanding the experience of living and dying with frailty in old age. Soc Sci Med 2012;75:1426\u201332. https:\/\/doi.org\/10.1016\/j.socscimed.2012.06.011; PMID: 22800918. DOI: 10.1016\/j.socscimed.2012.06.011","DOI":"10.1016\/j.socscimed.2012.06.011"},{"key":"ref75","doi-asserted-by":"crossref","unstructured":"Nicholson C, Gordon AL, Tinker A. Changing the way \u201cwe\u201d view and talk about frailty\u2026 Age Ageing 2017;46:349\u201351. https:\/\/doi.org\/10.1093\/ageing\/afw224; PMID: 27932367. DOI: 10.1093\/ageing\/afw224","DOI":"10.1093\/ageing\/afw224"}],"container-title":["European Cardiology Review"],"original-title":[],"link":[{"URL":"https:\/\/www.ecrjournal.com\/articleindex\/ecr.2025.57","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T10:56:11Z","timestamp":1764327371000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ecrjournal.com\/articleindex\/ecr.2025.57"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,26]]},"references-count":76,"URL":"https:\/\/doi.org\/10.15420\/ecr.2025.57","relation":{},"ISSN":["1758-3756","1758-3764"],"issn-type":[{"value":"1758-3756","type":"print"},{"value":"1758-3764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,26]]},"article-number":"e35"}}